Dissolution properties, solid-state transformation and polymorphic crystallization: Progesterone case study

Pharmaceutical Development and Technology

Volumn 19, Issue 7, 2014, Pages 779-788

  Araya Sibaja, Andrea Mariela ^a,b   Paulino, Amarilis Scremin ^a   Rauber, Gabriela Schneider ^a   Maduro Campos, Carlos Eduardo ^a   Cardoso, Simone Gonçalves ^a   Monti, Gustavo Alberto ^c   Heredia, Valeria ^d   Bianco, Ismael ^d,e,f   Beltrano, Dante ^d,e,g   Cuffini, Silvia Lucia ^a,e,h  

^a FEDERAL UNIVERSITY OF SANTA CATARINA   (Brazil)

^b UNIVERSIDAD DE COSTA RICA   (Costa Rica)

^c UNIVERSIDAD NACIONAL DE CÓRDOBA   (Argentina)

^d Centro de Excelencia en Productos y Procesos de Cordoba   (Argentina)

^e Facultad de Ciencias Naturales e Instituto M Lillo   (Argentina)

^f Universidad Nacional de La Rioja   (Argentina)

^g UNIVERSIDAD CATÓLICA DE CÓRDOBA   (Argentina)

^h Ministerio de Ciencia y Técnica de Córdoba   (Argentina)

Author keywords

Intrinsic dissolution rate; Phase transformation; Polymorphism; Progesterone; Solid state characterization

Indexed keywords

ACETONE; CHLORBUTOL; PROGESTERONE;

ARTICLE; CARBON NUCLEAR MAGNETIC RESONANCE; CONTROLLED STUDY; CRYSTALLIZATION; DRUG FORMULATION; DRUG SOLUBILITY; DRUG STRUCTURE; DRUG TRANSFORMATION; ENANTIOMER; IN VITRO STUDY; INFRARED SPECTROSCOPY; MECHANICAL STRESS; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; PRIORITY JOURNAL; RAMAN SPECTROMETRY; SCANNING ELECTRON MICROSCOPY; SOLID STATE; THERMAL ANALYSIS; X RAY POWDER DIFFRACTION;

CRYSTALLIZATION; MAGNETIC RESONANCE SPECTROSCOPY; POWDER DIFFRACTION; PROGESTERONE; PROGESTINS; SOLUBILITY; SPECTROSCOPY, FOURIER TRANSFORM INFRARED; SPECTRUM ANALYSIS, RAMAN; X-RAY DIFFRACTION;

EID: 84898725643     PISSN: 10837450     EISSN: 10979867     Source Type: Journal    
DOI: 10.3109/10837450.2013.829096     Document Type: Article

References (31)

1. Byrn S, Pfeiffer R, Stowell J. Solid-state chemistry of drugs. 2nd ed. Indiana: SSCI Inc.; 1999:574.
2. Brittain H, ed. Polymorphism in pharmaceutical solids. New York: Marcel Dekker Inc.; 1999.
3. Yu L. Physical characterization of polymorphic drugs: an integrated characterization strategy. Pharm Sci Technol Today 1998;1: 118-127.
4. Cimarosti Z, Castagnoli C, Rossetti M, et al. Development of drug substances as mixture of polymorphs: studies to control form 3 in casopitant mesylate. Org Process Res Dev 2010;14:1337-1346.
5. Lancaster RW, Karamertzanis PG, Hulme AT, et al. Racemic progesterone: predicted in silico and produced in the solid state. Chem Commun 2006;47:4921-4923.
6. Lancaster RW, Karamertzanis PG, Hulme AT, et al. The polymorphism of progesterone: stabilization of a "disappearing" polymorph by co-crystallization. J Pharm Sci 2007;96:3419-3431.
7. Hirvonen E. Progestins. Maturitas 1996;23:S13-S18.
8. Payne RS, Roberts RJ, Rowe RC, Docherty R. Examples of successful crystal structure prediction: polymorphs of primidone and progesterone. Int J Pharm 1999;177:231-245.
9. Cameroni R, Gamberini G, Bernabei MT, Facchini M. Polymorphism of progesterone. I. Preparation and characterization of polymorphic forms. Il Farmaco Edizione Pratica 1973;28: 621-635.
10. Barrio M, Espeau P, Tamarit JL, et al. Polymorphism of progesterone: relative stabilities of the orthorhombic phases I and II inferred from topological and experimental pressure-temperature phase diagrams. J Pharm Sci 2009;98:1657-1670.
11. Heredia V, Bianco ID, Tríbulo H, et al. Polyisoprene matrix for progesterone release: in vitro and in vivo studies. Int J Pharm 2009; 382:98-103.
12. Tripathi R, Biradar SV, Mishra B, Paradkar AR. Study of polymorphs of progesterone by novel melt sonocrystallization technique: a technical note. AAPS Pharm Sci Tech 2010;11: 1493-1498.
13. Larson AC, Von Dreele RB. General structure analysis system (GSAS) structure. Los Alamos National Laboratory; 2004:86-748.
14. Toby BH. EXPGUI, a graphical user interface for GSAS. J Appl Crystallogr Int Union Crystallogr 2001;34:210-213.
15. Stephens PW. Phenomenological model of anisotropic peak broadening in powder diffraction. J Appl Crystallogr 1999;32: 281-289.
16. Harris R. Nuclear magnetic resonance spectroscopy. London: Longman Scientific and Technical; 1994.
17. Bräuniger T, Wormald P, Hodgkinson P. Improved proton decoupling in NMR spectroscopy of crystalline solids using the S PINAL-64 sequence. Monatsh Chem 2002;133:1549-1554.
18. Legendre B, Feutelais Y, Defossemont G. Importance of heat capacity determination in homogeneous nucleation: application to progesterone. Thermochim Acta 2003;400:213-219.
19. USP. United State Pharmacopeia. 30th ed. Rockville: United State Convention; 2007.
20. Taghizadeh SM, Mashak A, Jamshidi A, Imani M. Study of progesterone release mechanisms from a silicone matrix by a new analytical method. J Appl Polym Sci 2004;91:3040-3044.
21. Farmacopeia Brasileira, Volume 2/Agência Nacional de Vigilância Sanitária, Anvisa, Brasília; 2010.
22. Wang F, Wachter JA, Antosz FJ, Berglund KA. An investigation of solvent-mediated polymorphic transformation of progesterone using in situ Raman spectroscopy. Org Process Res Dev 2000;4:391-395.
23. Narang AS, Rao VM, Raghavan KS. Excipient compatibility. Developing solid oral dosage forms pharmaceutical theory and practice. 1st ed. Oxford: Elsevier Inc.; 2009:125-145.
24. Yu L. Feasibility studies of utilizing disk intrinsic dissolution rate to classify drugs. Int J Pharm 2004;270:221-227.
25. Defossemont G, Randzio SL, Legendre B. Contributions of calorimetry for Cp determination and of scanning transitiometry for the study of polymorphism. Cryst Growth Des 2004;4:1169-1174.
26. Reading M, Craig DQM. Principles of differential scanning calorimetry. Thermal analysis of pharmaceuticals. 1st ed. Boca Raton: Taylor and Francis; 2007:1-22.
27. Brittain HG. Polymorphism and solvatomorphism 2010. J Pharm Sci 2012;101:464-484.
28. Muramatsu M, Iwahashi M, Takeuchi U. Thermodynamic relationship between alpha-and beta-forms of crystalline progesterone. J Pharm Sci 1979;68:175-177.
29. Sehic S, Betz G, Hadzidedic S, et al. Investigation of intrinsic dissolution behavior of different carbamazepine samples. Int J Pharm 2010;386:77-90.
30. Lancaster RW, Harris LD, Pearson D. Fifty-year old samples of progesterone demonstrate the complex role of synthetic impurities in stabilizing a metastable polymorph. Cryst Eng Comm 2011;13: 1775.
31. Dunitz JD, Bernstein J. Disappearing polymorphs. Acc Chem Res 1995;28:193-200.